GKB
GKB Ophthalmics financials
- Market cap
- ₹33 Cr
- Sector
- Healthcare
What GKB Ophthalmics Ltd. does
GKB Ophthalmics manufactures plastic and glass ophthalmic lenses at its Goa (India) facility, which includes multiple manufacturing units (referenced as Unit I and Unit II) producing lenses used in prescription eyewear. It distributes internationally through wholly-owned and step-down subsidiaries: GKB Ophthalmics Products FZE in Sharjah (UAE), Lensco - The Lens Company in New Jersey (USA), Prescription Optical Products LLC in Dubai (which also handles contact lenses), and a newly incorporated Prime Ophthalmics Products PTY in South Africa set up to serve African demand. A separate subsidiary, GSV Ophthalmics Private Limited, was incorporated to produce Hi-Index ophthalmic lenses, but that project has since become financially unviable. The company faces stiff competition from lower-priced Chinese lens imports into India and is pursuing anti-dumping duty relief with authorities.
Segments
- Domestic lens manufacturing
- Overseas subsidiaries - lens trading/distribution
- Hi-Index lens project (GSV Ophthalmics)
- Manufacturing units
- Multiple units (Unit I & Unit II) at Goa, India
- Global subsidiaries
- 5 (UAE, USA, Dubai, South Africa, India)
- Overseas presence
- UAE (Sharjah), USA (New Jersey), Dubai, South Africa
- Permanent employees
- 170 (FY25)
- Quality certification
- ISO 9001:2015 (TUV SUD South Asia)
- Recent capacity investment
- 2 new advanced lens development & coating machines (sourced from Bangalore)
Quarterly results
Q1 FY27: revenue up 2.3%, net profit up 389.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 26 | 31 | 32 | 30 +15% | 57 +120% | 30 −4% | 33 +2% |
| EBITDA | -0 | -1 | -3 | 1 | 3 +5133% | 2 +277% | 3 +208% | 3 +229% |
| Net profit | -1 | -2 | -4 | -1 | 2 +260% | 1 +137% | 1 +127% | 2 +389% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −0.3% YTD
YTD: ₹65 on 17 Aug 2026 → ₹64.79. High ₹71.52 (8 Sept 2026), low ₹60.9 (19 Aug 2026).
Financials, as filed
Revenue grew 30.0% a year over 2 years, FY24 to FY26. Operating margin widened to 5.7%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹88 Cr | ₹109 Cr | ₹149 Cr |
| Operating profit | ₹0 Cr | ₹-3 Cr | ₹9 Cr |
| Operating margin | 0.5% | -2.6% | 5.7% |
| Interest | ₹2 Cr | ₹2 Cr | ₹3 Cr |
| Depreciation | ₹3 Cr | ₹3 Cr | ₹3 Cr |
| Net profit | ₹-3 Cr | ₹-7 Cr | ₹3 Cr |
| Net margin | -3.4% | -6.5% | 2.0% |
| Cash from operations | ₹4 Cr | ₹-3 Cr | ₹-4 Cr |
| Free cash flow | ₹2 Cr | ₹-6 Cr | ₹-5 Cr |
| ROCE | -1.0% | -6.0% | 11.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| Reserves | ₹58 Cr | ₹58 Cr | ₹58 Cr | ₹55 Cr | ₹48 Cr | ₹48 Cr |
| Borrowings | ₹12 Cr | ₹12 Cr | ₹11 Cr | ₹11 Cr | ₹15 Cr | ₹12 Cr |
| Other liabilities | ₹32 Cr | ₹35 Cr | ₹38 Cr | ₹43 Cr | ₹74 Cr | ₹68 Cr |
| Total liabilities | ₹107 Cr | ₹110 Cr | ₹112 Cr | ₹114 Cr | ₹141 Cr | ₹132 Cr |
| Fixed assets | ₹24 Cr | ₹23 Cr | ₹19 Cr | ₹18 Cr | ₹17 Cr | ₹15 Cr |
| Capital work in progress | ₹1 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Investments | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Other assets | ₹80 Cr | ₹82 Cr | ₹87 Cr | ₹91 Cr | ₹119 Cr | ₹111 Cr |
| Total assets | ₹107 Cr | ₹110 Cr | ₹112 Cr | ₹114 Cr | ₹141 Cr | ₹132 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025.
- Promoters
- 51.1%
- FIIs
- 1.8%
- Public
- 47.1%
Since Jun 2025
- Promoters +0.09 pp
- Public −0.09 pp
- FIIs 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 50.9%, FIIs 1.8%, Public 47.4%.Dec '23: Promoters 50.9%, FIIs 1.8%, Public 47.3%.Mar '24: Promoters 50.9%, FIIs 1.8%, Public 47.3%.Jun '24: Promoters 51.0%, FIIs 1.8%, Public 47.3%.Sep '24: Promoters 51.0%, FIIs 1.8%, Public 47.3%.Dec '24: Promoters 51.0%, FIIs 1.8%, Public 47.2%.Mar '25: Promoters 51.0%, FIIs 1.8%, Public 47.2%.Jun '25: Promoters 51.1%, FIIs 1.8%, Public 47.2%.Sep '25: Promoters 51.1%, FIIs 1.8%, Public 47.2%.Dec '25: Promoters 51.1%, FIIs 1.8%, Public 47.1%.Mar '26: Promoters 51.1%, FIIs 1.8%, Public 47.1%.Jun '26: Promoters 51.1%, FIIs 1.8%, Public 47.1%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Dhanpat Mishrimal Kothari newly disclosed 1.01% held
- Tanvi Jignesh Mehta +0.14 pp 4.82% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of GKB Ophthalmics Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Krishna Gopal Gupta | 17.91% | unchanged |
| Vikram Gupta | 8.39% | unchanged |
| Gaurav Gupta | 8.09% | unchanged |
| Veena Gupta | 5.97% | unchanged |
| Krishnagopal Gupta And Sons | 5.97% | unchanged |
| Krishna Murari Gupta | 5.54% | unchanged |
| Tanvi Jignesh Mehta | 4.82% | +0.14 pp |
| Shefali Chawla | 4.81% | unchanged |
| Somo Vision Co. Ltd. | 3.97% | unchanged |
| Brijendra Kumar Gupta | 3.31% | unchanged |
| Coeus Global Opportunities Fund FPI fund | 1.79% | unchanged |
| Lalit Kumar Gupta | 1.40% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse GKB Ophthalmics Ltd.
Guides on how to read this kind of business and the numbers that matter.